This Report Provides In-Depth Analysis of the Hematology Testing Market Report Prepared by P&S Intelligence, Segmented by Product (Instruments, Consumables), Test (Routine Hematology Tests, Special Hematology Tests), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Geographical Outlook for the Period of 2019 to 2032
Explore the market potential with our data-driven report
Hematology Testing Market Outlook
The global hematology testing market size stood at USD 4789.9 million in 2024, which is expected to reach USD 6886.5 million by 2032, advancing at a CAGR of 4.8% during 2025–2032. This can prominently be due to the rising prevalence of blood-related diseases and the surging adoption of high-throughput hematology analyzers alongside population aging and advanced diagnostic equipment developments.
In addition, the medical tests performed in hematology serve crucial functions for diagnosing different blood-based illnesses while supporting both their evaluation and therapeutic management for patients with anemia, leukemia, and lymphoma in addition to clotting disorder patients. Automation technology advances in the market through the development of automated hematology analyzers, flow cytometry systems, and molecular diagnostic methods that enhance testing capabilities with rapid results of higher accuracy at increased speed and efficiency.
The demand rises for point-of-care testing (POCT) together with personalized medicine trends redefines how the market develops. With the introduction of portable hematology analyzers together with POC devices gained popularity because emergency care providers and remote locations need quick and accessible diagnostic solutions. Market expansion results from both patients becoming more aware about preventive healthcare and increased access to treatment reimbursement policies for diagnostic tests.
The hematology testing market will continue expanding due to its newest technological development and increasing disease instances supported by rising demand for expedited medical diagnoses and personalized therapeutic approaches.
Hematology Testing Market Emerging Trends
Rising Demand for Point-of-Care Hematology Diagnostics Is the Key Trend
The market is shifting towards automation in hematology analyzers plus advanced technology features which improves test precision while speeding up results. There is a growing adoption for point-of-care testing (POCT) because people require faster blood tests at different locations, which pushes the market towards simple portable POCT devices.
Hematology medical testing now prefer using polymerase chain reaction (PCR) and next-generation sequencing (NGS) technology to find blood disorders and leukemia genetic fault patterns.
Hematology research develops companion tests because doctors need product-specific details to design personalized therapy for each patient's unique healthcare condition.
While the initial investment in POC devices can be high, long-term cost savings make them an attractive option. The ability to conduct tests in real-time reduces the need for hospitalization, extended lab processing times, and follow-up visits, which in turn lowers healthcare costs.
Miniaturization of diagnostic devices and advancements in technology have made it possible to develop compact, user-friendly, and highly accurate POC hematology testing instruments. These devices can perform sophisticated tests like complete blood counts (CBCs) and other hematology assays at the point of care.
The blood testing centers and medical labs are rapidly adopting high-throughput hematology analyzer instruments to process more samples faster.
Growing Investments in Healthcare Infrastructure and Diagnostic Labs Are the Major Growth Driver
The growing number of blood-related diseases like anemia, leukemia, and lymphoma, which makes patients need more hematology testing. This increase in blood condition cases makes healthcare providers need regular diagnostic testing to properly treat patients.
The aging population is more affected by various hematological conditions, due to which there is a surge in the need for regular blood tests and diagnostic procedures.
Individuals nowadays are aware of the importance of early diagnosis and preventive healthcare, which requires higher rates of regular blood test and health checkups.
The improvement and development of healthcare in the growing economies need the requirement of diagnostic services, including hematology testing.
The rise of private and public investments in diagnostic laboratories has led to the adoption of more advanced hematology testing equipment. These modern labs are now better equipped with automated hematology analyzers, advanced flow cytometry systems, and molecular diagnostic tools, enabling faster, more accurate results.
The reimbursement policies for diagnostic tests are making hematology testing more accessible and affordable, encouraging greater utilization of these services.
In many regions, government initiatives to improve healthcare accessibility and quality have led to increased funding for diagnostic facilities and healthcare systems. For instance, investments in public health programs to address chronic diseases like anemia, leukemia, and hemophilia have driven demand for hematology testing.
Hematology Testing Market Segmentation Analysis
Product Insights
The consumables category generated a larger revenue share, of around 75%, in 2024, and it is also expected to witness a higher CAGR, of around 7%, in the forecast period.
This is mainly due to the extensive use of a wide range of test kits and reagents to perform hematology testing, while catering to the requirements of end users.
The segments of reagents for chemical blood cell analysis, stains for cell viewing, and controls for instrument validation account for most of the hematology testing market.
All medical facilities depend heavily on these essentials because they require them to run successful tests. These consumables are considered to be the reoccurring revenue model in the market.
The consumables are needed each time hematology testing is performed, building a directly proportional relationship between consumables and instruments.
Medical facilities depend on automated hematology analyzers which need specific product types to work well and this growing trend creates more need for top-quality reagents and controls. Consumables keep hematology testing accurate so they remain the leading part of the market.
The products analyzed in the report are::
Instruments
Analyzers
Fully automated
Semi-automated
Flow cytometers
Consumables (Larger and Faster-Growing Category)
Reagents
Stains
Controls & calibrators
Test Insights
The routine hematology tests represent the larger category with a revenue share of around 80% in 2024.
This is because so many patients regularly get these tests done in medical labs and healthcare facilities all over the world.
Doctors use complete blood count tests as the main healthcare testing method because they help check patient health and detect blood disorders plus infections. These tests also show how treatment works for patients.
Instrumentation of CBCs for whole-person health evaluations and medical treatment planning keeps these tests in front. Hematology tests will stay popular because they are easy to afford and necessary for basic medical examination results.
The current system for standard blood test processing and automation through testing machines helps expand this market segment.
Regular scheduling and disease diagnosis lead clients to consistently request hematology testing which keeps this segment leading in market size.
The tests analyzed in the report are:
Routine Hematology Tests (Larger Category)
Special Hematology Tests (Faster-Growing Category)
End User Insights
The hospitals category accounted for the largest revenue share, of around 45%, in 2024.
This is on account of the increasing number of hospitals and high patient influx in hospitals in comparison to other diagnostic centers.
Also, hospitals establish contracts with vendors to purchase analyzers and related consumables on a regular basis. In addition, the demand for hematology testing among patients is high, who are suffering from cancer and diabetes.
The availability of skilled healthcare professionals with knowledge and expertise in treating various acute and chronic diseases also draws the majority of patients to hospitals as opposed to other healthcare settings.
As a result of the increase in the number of people suffering from various acute and chronic diseases, hospitals are being encouraged to equip advanced hematology analyzers, which is boosting the industry growth.
In addition, the demand for hematology testing in hospitals is being driven by the surge in the aging population, digitalization in the healthcare industry, and the widescale adoption of healthcare insurance.
The end users analyzed in the report are:
Hospitals (Largest Category)
Diagnostic Laboratories
Blood Banks
Drive strategic growth with comprehensive market analysis
North America led the hematology diagnostics market in 2024, with a revenue share of 45%. This is primarily attributable to the growing prevalence of various types of blood diseases, favorable patient demographics, and reimbursement policies in the region. The demand is mainly surging across professional healthcare settings to treat the rising patient population in the U.S. and Canada. Furthermore, the surging prevalence of blood-related disorders, such as anemia, sickle cell disease, and thalassemia, are driving the need for hematology analyzers and consumables in the region.
North America is one of the major hematology analyzer replacement markets. Many laboratories and hospitals have semi-automatic or automatic hematology analyzers. In addition, the high healthcare expenditure, numerous R&D activities, and the strong presence of industry players are other factors intensifying the market growth.
North American countries, particularly the U.S. and Canada, have high healthcare spending. This investment ensures the availability of state-of-the-art diagnostic infrastructure, which increases the adoption of hematology testing in clinical settings. Insurance coverage and reimbursement for diagnostic tests also contribute to the market growth, making hematology tests more accessible to a larger population.
The aging population in North America is a significant factor driving the demand for hematology testing. Older adults are at higher risk for blood disorders such as anemia and leukemia, which requires ongoing diagnostics and monitoring. This demographic shift is leading to greater demand for routine blood tests and early diagnosis of chronic conditions, further boosting the hematology testing market.
These regions are covered:
North America (Largest Region)
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia-Pacific
China
Japan
Australia
India
South Korea
Latin America
Brazil
Mexico
Middle East & Africa
U.A.E.
Saudi Arabia
South Africa
Hematology Testing Market Competitive Landscape
The hematology testing market is moderately consolidated with both international corporations and regional specialists present in the field. Major vendors like Siemens Healthineers, Abbott Laboratories, and Beckman Coulter maintain strong positions because they deliver complete solution lines plus operate extensive channels and trusted product brands. These major companies develop complete hematology analyzer systems alongside reagents and supply products and sell them to different medical facilities. The market contains multiple smaller businesses that target special healthcare areas or geographic areas even though it remains divided.
Companies developing unique testing solutions benefit from changes in technology and raised user demands even though larger organizations maintain market dominance. The industry gets new technology through smaller companies because molecular diagnostics and personalized medical devices help them identify special testing markets. The ever-changing business environment drives market competitiveness and helps create new products to balance the size of companies in this industry.
Hematology Testing Companies:
Beckman Coulter Inc.
Siemens Healthineers
Mindray Medical International Limited
F. Hoffmann-La Roche Ltd.
Sysmex Corporation
Cardinal Health Inc.
Abbott Laboratories
HORIBA Medical
Bio-Rad Laboratories, Inc.
Diatron MI Zrt.
Boule Diagnostics AB
Thermo Fisher Scientific Inc.
Hematology Testing Market News
In September 2023, Abbott announced it had completed the acquisition of Bigfoot Biomedical.
Want a report tailored exactly to your business need?
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws